Biopharma's hot topic - weight loss drugs – will take center stage when Cantor’s Louise Chen speaks at the Seeking Alpha Investing Summit on June 18, 2024. Register below to attend and learn about how the GLP-1 drug market is anticipated to become the best-selling drug class in 2024. https://ow.ly/YW4P50SiQ4u
Cantor Fitzgerald’s Post
More Relevant Posts
-
#Biopharma deal values are surging compared to 2022, but several uncertainties are weighing on dealmaking sentiment. Explore how M&A is affecting #dealmaking tailwinds in the biopharma industry. Read now: https://bit.ly/47Eh05R #PharmaDeals #ProtectionLink #ForecastLink
To view or add a comment, sign in
-
-
Episode 20 of #AstonishingHealthcare is packed with information about #drugprices and the forces that drive them in the United States. It was a minor miracle that schedules lined up for this one, and A. J. Loiacono and Antonio Ciaccia could join us to share their insights and explain why #NADAC is a "ray of sunshine" (i.e., source of #truth) in an otherwise murky but essential part of the pharmaceutical #supplychain. They discuss: ↘️ The changes to NADAC and why we're seeing [substantial] deflationary pressure 💡 The unique aspects of NADAC that make it broadly helpful to the market 🔎 Why drug prices behave unlike the price of any other goods in our economy 🎧 Listen to the full episode here: https://okt.to/0fcxGg
To view or add a comment, sign in
-
Episode 20 of #AstonishingHealthcare is packed with information about #drugprices and the forces that drive them in the United States. It was a minor miracle that schedules lined up for this one, and A. J. Loiacono and Antonio Ciaccia could join us to share their insights and explain why #NADAC is a "ray of sunshine" (i.e., source of #truth) in an otherwise murky but essential part of the pharmaceutical #supplychain. They discuss: ↘️ The changes to NADAC and why we're seeing [substantial] deflationary pressure 💡 The unique aspects of NADAC that make it broadly helpful to the market 🔎 Why drug prices behave unlike the price of any other goods in our economy 🎧 Listen to the full episode here: https://okt.to/Nbp2qu
To view or add a comment, sign in
-
Episode 20 of #AstonishingHealthcare is packed with information about #drugprices and the forces that drive them in the United States. It was a minor miracle that schedules lined up for this one, and A. J. Loiacono and Antonio Ciaccia could join us to share their insights and explain why #NADAC is a "ray of sunshine" (i.e., source of #truth) in an otherwise murky but essential part of the pharmaceutical #supplychain. They discuss: ↘️ The changes to NADAC and why we're seeing [substantial] deflationary pressure 💡 The unique aspects of NADAC that make it broadly helpful to the market 🔎 Why drug prices behave unlike the price of any other goods in our economy 🎧 Listen to the full episode here: https://okt.to/L73BQ5
To view or add a comment, sign in
-
Episode 20 of #AstonishingHealthcare is packed with information about #drugprices and the forces that drive them in the United States. It was a minor miracle that schedules lined up for this one, and A. J. Loiacono and Antonio Ciaccia could join us to share their insights and explain why #NADAC is a "ray of sunshine" (i.e., source of #truth) in an otherwise murky but essential part of the pharmaceutical #supplychain. They discuss: ↘️ The changes to NADAC and why we're seeing [substantial] deflationary pressure 💡 The unique aspects of NADAC that make it broadly helpful to the market 🔎 Why drug prices behave unlike the price of any other goods in our economy 🎧 Listen to the full episode here: https://okt.to/pB3r5C
To view or add a comment, sign in
-
“This is a story about two big dominators here: Eli Lilly and Novo Nordisk. Lilly and Novo are going to be dominating this space in the foreseeable future,” said our Head of BioPharma Research, Rahul R Jasuja, PhD on Schwab Network. With a surge of GLP-1 drugs into the market and heightened interest, Rahul anticipates that Eli Lilly and Company (LLY) and Novo Nordisk (NVO) will maintain their stronghold over the next decade. During the interview, Rahul also delves into the proprietary process behind our GLP-1 monitor tool, which enhances research for investors by extracting valuable insights from analyst reports, leading to a robust and high-quality market consensus and offering more accurate longer-term forecasts. Watch the interview for Rahul's outlook on the GLP-1 drug market, insights on other emerging players to follow, and more: https://hubs.li/Q02rKzXH0
Biotech’s Next Gold Rush: Weight-Loss Drugs | The Watch List| Schwab Network
schwabnetwork.com
To view or add a comment, sign in
-
A lot of misperceptions and confusion out there. Here is a good explanation about the need to compound as a solution for #medication #shortages. There is a huge intentional tendency of confounding….. #compoundingpharmacy #medicationshortages
FDA guidance allows compounding pharmacies to make “essentially copies” of FDA-approved drugs when those drugs are listed as “currently in shortage” on the FDA drug shortage list — as both semaglutide and tirzepatide long have been. Reporters often ask us why compounded versions of those GLP-1s are so much less expensive than the branded drug. This report below appears to support what we tell those reporters: The active pharmaceutical ingredient in those drugs is inexpensive — and I would add: Compounding pharmacies aren’t looking to gouge their patients.
To view or add a comment, sign in
-
We are almost halfway through 2024! 😲 And there are still some huge blockbuster products facing generic and biosimilar competition in the second half of the year, including Bristol Myers Squibb's #Sprycel. 💊 Here is a reminder of the top drugs losing US exclusivity: #generics #pharmaindustry #patentexpiry #LOE #biosimilars https://lnkd.in/g8CStUyF
The top 10 drugs losing US exclusivity in 2024
fiercepharma.com
To view or add a comment, sign in
-
Episode 20 of #AstonishingHealthcare is packed with information about #drugprices and the forces that drive them in the United States. It was a minor miracle that schedules lined up for this one, and A. J. Loiacono and Antonio Ciaccia could join us to share their insights and explain why #NADAC is a "ray of sunshine" (i.e., source of #truth) in an otherwise murky but essential part of the pharmaceutical #supplychain. They discuss: ↘️ The changes to NADAC and why we're seeing [substantial] deflationary pressure 💡 The unique aspects of NADAC that make it broadly helpful to the market 🔎 Why drug prices behave unlike the price of any other goods in our economy 🎧 Listen to the full episode here: https://okt.to/F10z2R
To view or add a comment, sign in